10-Q: Moleculin Biotech Reports Third Quarter 2024 Results, Advances Annamycin Clinical Program

Moleculin Biotech's Q3 2024 report highlights progress in Annamycin clinical trials and financial updates, including a recent equity raise.

Summary

• Moleculin Biotech reported its financial results for the third quarter of 2024, showing a net loss of $10.6 million, or $2.85 per share.
• The company's research and development expenses were $4.9 million for the quarter, while general and administrative expenses totaled $2.2 million.
• For the nine months ended September 30, 2024, the net loss was $19.9 million, or $6.83 per share.
• The company's cash and cash equivalents stood at $9.4 million as of September 30, 2024.
• Moleculin completed a public offering in August 2024, raising gross proceeds of $5.5 million through the sale of common stock and warrants.
• The company is preparing for a Phase 3 clinical trial for Annamycin in AML, with plans to enroll approximately 45 subjects by Q3 2025 and 90 subjects by the second half of 2026.
• Preliminary data from the MB-106 trial showed a 36% complete remission rate and a 41% complete remission composite rate for all subjects, with higher rates in 2nd line AML patients.
• The company has received Orphan Drug Designation for Annamycin in the US and Europe, and has secured patents for its liposomal Annamycin formulation.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and intellectual property, the company's financial situation is concerning with significant losses and a need for substantial additional funding. The ongoing SEC investigation also adds a layer of uncertainty.

Positives

• The company successfully raised $5.5 million through a public offering, strengthening its financial position.
• Annamycin has shown promising efficacy data in the MB-106 trial, with a 50% complete remission rate in 2nd line AML patients.
• The company has secured Orphan Drug Designation for Annamycin in both the US and Europe, providing potential market exclusivity.
• New patents for Annamycin's liposomal formulation provide strong intellectual property protection.
• The company is actively progressing its clinical programs, including the Phase 3 MIRACLE trial for Annamycin and the Phase 2 study for WP1066.
• Annamycin has shown no cardiotoxicity in clinical trials to date, a significant advantage over other anthracyclines.

Negatives

• The company reported a net loss of $10.6 million for the third quarter of 2024 and $19.9 million for the nine months ended September 30, 2024.
• The company's cash balance is $9.4 million as of September 30, 2024, which is not sufficient to fund operations for a year.
• The company has an accumulated deficit of $151.5 million since inception.
• The company is dependent on raising additional capital to fund its operations and clinical trials.
• The company has incurred significant transaction costs related to warrant liabilities.
• The company is subject to an ongoing SEC investigation, which has incurred expenses of $0.2 million and $1.4 million for the nine months ended September 30, 2024 and 2023, respectively.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional funding.
• There is no guarantee that the company will be able to raise the necessary capital to fund its operations and clinical trials.
• The company is subject to an ongoing SEC investigation, which could result in penalties or other adverse actions.
• Clinical trials may not be successful, and regulatory approvals may not be granted.
• The company is dependent on third-party manufacturers for its drug products.
• The company faces competition from other pharmaceutical companies.
• The company is subject to risks related to intellectual property protection.
• The company is subject to risks related to healthcare reform measures and drug pricing regulations.

Future Outlook

The company plans to initiate a Phase 3 clinical trial for Annamycin in AML, with enrollment expected to begin in early 2025. They also plan to release topline data from the MB-107 trial for soft tissue sarcoma lung metastases in the near future. The company anticipates needing approximately $15 million in additional funding to support operations into the third quarter of 2025.

Management Comments

• Management believes that Annamycin may allow a majority of AML and Advanced STS patients to benefit from anthracycline treatment due to its lack of cardiotoxicity and ability to avoid multidrug resistance.
• Management believes the Phase 1B/2 trial has been successful in establishing safety and efficacy of Annamycin in combination with Cytarabine for the treatment of AML.
• Management believes the results demonstrated by AnnAraC in 2nd line subjects substantially exceeds the performance reported by any drug currently approved for use in 2nd line AML.

Industry Context

The company is operating in the competitive pharmaceutical industry, focusing on oncology treatments. The development of Annamycin, a next-generation anthracycline with reduced cardiotoxicity, addresses a significant unmet need in cancer therapy. The company's focus on AML and soft tissue sarcoma aligns with areas of high unmet medical need and significant market potential. The company's strategy of seeking outlicensing or outsourcing opportunities is common in the biotech industry, particularly for smaller companies.

Comparison to Industry Standards

• The reported 36% complete remission rate and 41% complete remission composite rate in the MB-106 trial for all AML subjects is promising, especially when compared to historical data for AML treatments.
• The 50% complete remission rate and 60% complete remission composite rate in 2nd line AML patients in the MB-106 trial is significantly higher than the results of currently approved drugs for 2nd line AML.
• The lack of cardiotoxicity observed with Annamycin in clinical trials is a significant advantage compared to traditional anthracyclines like doxorubicin, which are known for their cardiotoxic side effects.
• The company's focus on a lipid-based delivery system for Annamycin is a novel approach that could improve drug efficacy and reduce toxicity, setting it apart from other treatments.
• The company's strategy of pursuing Orphan Drug Designation is a common approach for companies developing treatments for rare diseases, providing potential market exclusivity and other benefits.
• The company's reliance on third-party manufacturers is a common practice in the biotech industry, but it also introduces risks related to supply chain and quality control.
• The company's need for additional funding is typical for clinical-stage biotech companies, and its strategy of seeking a combination of equity, debt, and other funding sources is a common approach.

Legal Proceedings

• The company received a subpoena from the SEC in March 2022 requesting information and documents related to certain individuals and entities, and materials related to the development of and statements regarding the company's drug candidate for the treatment of COVID-19.
• The company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter.

Related Party Transactions

• The company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI), with total expenses of $59,000 for each of the three months ended September 30, 2024 and 2023, respectively, and $176,000 for the nine months ended September 30, 2024 and 2023, respectively.
• The company recorded approximately $12,000 in sublease income from a related party for the three months ended September 30, 2024 and 2023, and $37,000 for the nine months ended September 30, 2024 and 2023.
• Accounts payable includes $20,000 and $67,000 as of September 30, 2024 and December 31, 2023, respectively, for related party payables.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future equity offerings.
• Employees may be impacted by the company's financial instability and potential need for cost-cutting measures.
• Customers (patients) may benefit from the development of new treatments for AML and soft tissue sarcoma.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.
• The company's success is dependent on the support of its stakeholders, including investors, employees, and research partners.

Next Steps

• The company will begin contracting with MIRACLE trial sites in the second half of 2024.
• The first subject is expected to be treated in the MIRACLE trial in the first quarter of 2025.
• Recruitment and interim data for the MIRACLE trial (n=~45) are expected in the fourth quarter of 2025.
• Interim efficacy and safety data (n=~90) for the MIRACLE trial are expected to be unblinded in the second half of 2026.
• Enrollment of 3rd line subjects in the MIRACLE2 trial is expected to begin in 2027.
• Enrollment of 2nd line subjects in the MIRACLE trial is expected to end in 2027.
• Primary endpoint efficacy data for 2nd line subjects in the MIRACLE trial is expected in 2028.
• The company plans to begin submission of a new drug application (NDA) for the treatment of R/R AML in the second half of 2028.

Key Dates

Keywords

Annamycin, AML, clinical trials, Orphan Drug Designation, warrant liability, reverse stock split, Phase 3, MIRACLE trial, cardiotoxicity, pre-funded warrants, stock offering, WP1066, glioblastoma, soft tissue sarcoma, regulatory approval